Score Breakdown
Below average.
Kodiak Sciences is a binary clinical-stage biotech with no revenue, high cash burn (~$55M/quarter), and a 72x P/B ratio. The Dec 2025 capital raise extended runway to 2H 2027 but at massive dilution. The investment case is entirely a bet on Phase 3 readouts for tarcocimab (GLOW2 in Q1 2026) and KSI-501 (DAYBREAK in Q3 2026). The $1.3B market cap embeds meaningful probability of success, but given the prior Phase 3 failure in DME, intense competition from Vabysmo/Eylea, and the company's history of clinical disappointments, the risk/reward is roughly balanced. The CFO's adoption of a sell plan during going concern disclosure is a notable negative signal. High short interest (14.9%) creates potential squeeze dynamics but also reflects informed skepticism. At $24.86, the stock prices in perhaps a 25-30% probability of major commercial success, which seems approximately fair given the pipeline breadth but offset by execution risk and competitive pressure. There are better risk/reward setups elsewhere.
Negative cash flow. Can't value it.
Major red flags in SEC filings.
Minimal.
No data.
Clock is ticking.
Significant shorts.
Below average.
🐻 Why Bears Hate It
The bear thesis relies on the traumatic August 2023 failure of tarcocimab in diabetic macular edema (DME), which decimated the stock price. Bears argue the company is a 'one-platform' risk with no revenue and a history of over-promising. Despite the recent capital raise, KOD still maintains a high net loss ($54.3M in Q2 2025) and a Price-to-Book ratio of ~72x, which is significantly higher than the biotech industry average of 2.7x (Simply Wall St, Feb 2026).
🔍 What's In The SEC Filings
The company faces an immediate liquidity crisis with less than one year of runway, high dilutive potential from outstanding options, and insiders initiating sell plans despite the financial distress.
Explicit management admission of substantial doubt regarding the entity's ability to continue operations.
“As a result, there is substantial doubt regarding the Company's ability to continue as a going concern.”
The company reported a net loss of $173.2 million for the first nine months of 2025 with only $72.0 million in cash remaining, indicating that existing capital is insufficient for the next 12 months.
The Chief Financial Officer adopted a share disposal plan during a period of extreme financial instability.
“John Borgeson, Chief Financial Officer... Adoption September 29, 2025... 120,000 [shares to be sold].”
CFO adoption of a Rule 10b5-1 trading arrangement to sell 120,000 shares immediately preceding the quarterly disclosure of insolvency risk suggests a lack of confidence in the company's recovery or upcoming financing terms.
Heavy reliance on the sale of future royalties to a single investment group using Level 3 valuation inputs.
“The Company has historically funded its operations primarily through the issuance of common stock and the sale of future royalties... based on the Company's current estimates of future royalties expected to be paid to Baker Bros. Advisors, LP.”
Selling future royalties creates a hidden liability that encumbers future cash flows; the valuation of this liability relies on 'unobservable inputs' (Level 3), allowing management significant discretion in financial reporting of these obligations.
Loss-making sublease and impairment of corporate real estate assets.
“The remaining lease cost to be recognized by the Company exceeded the anticipated sublease income and, as a result, the Company recognized a non-cash lease impairment expense of $1.9 million.”
Management over-extended on facility leases (1200 Page Mill Road) and was forced to sublease at a loss, indicating poor capital allocation and forecasting.
The intrinsic value must be heavily discounted for the high probability of bankruptcy or highly dilutive 'rescue' financing; the current share price likely does not fully reflect the 'substantial doubt' going concern status and the CFO's exit timing.
Significant concentration risk with Baker Bros Advisors; extremely high stock-based compensation ($45.6M for nine months) despite the company's failing financial health; and potential for 'embedded leases' in manufacturing agreements to complicate the balance sheet.
At the current burn rate, this company will need to raise money or die.